

Resource Summary Report

Generated by [RRID](#) on Aug 15, 2026

CINSignatureQuantification

RRID:SCR_028614

Type: Tool

Proper Citation

CINSignatureQuantification (RRID:SCR_028614)

Resource Information

URL: <https://github.com/markowetzlab/CINSignatureQuantification>

Proper Citation: CINSignatureQuantification (RRID:SCR_028614)

Description: Software R package to quantify the activity of signatures of chromosomal instability from absolute copy number profiles. Used to quantifying copy number signatures from absolute copy number profiles.

Resource Type: software toolkit, source code, software resource

Keywords: Quantifying copy number signatures, absolute copy number profiles, signatures of chromosomal instability,

Availability: Free, Available for download, Freely available

Resource Name: CINSignatureQuantification

Resource ID: SCR_028614

License URLs:

<https://github.com/markowetzlab/CINSignatureQuantification?tab=License-1-ov-file>

Record Creation Time: 20260630T043850+0000

Record Last Update: 20260815T183318+0000

Ratings and Alerts

No rating or validation information has been found for CINSignatureQuantification.

No alerts have been found for CINSignatureQuantification.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Xu S, et al. (2026) Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(12), e13086.

Malacrida B, et al. (2026) 3D pentaculture model unveils malignant cell-driven macrophage polarization in high-grade serous ovarian cancer. *Nature communications*, 17(1).

Bose A, et al. (2025) APOBEC3A-Induced DNA Damage Drives Polymerase ?? Dependency and Synthetic Lethality in Cancer. *bioRxiv : the preprint server for biology*.

Bergsma P, et al. (2025) Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma. *Molecular cancer therapeutics*, 24(12), 1989.